The US adult malignant glioma therapeutics market size stood at around USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period
Gliomas are the type of tumour starting at glial cells of the brain and spine are the most common types of brain tumours. According to Atlas of Genetics and Cytogenetics in Oncology and Hematology, glioma comprises of about 30% of the brain tumours and 70% of all the malignant tumours. Glioblastoma multiforme (GBM) is the most aggressive and difficult to treat form of the disease with median survival rate of 12 months
Market Drivers and Restraints
Growing prevalence of the disease, increase in aging population, huge unmet need, poor survival rate, and lack of effective therapies for the complete cure of the disease leverages great opportunity for the players to invest in the research and development of glioma therapies
There is even a study which shows significant increase in incidence from 0.73 to 4.49 per 100,000 over the 10-year period. An increasing incidence of GBM is becoming evident, while the median survival remains low which affects the effectives of therapies for complete cure
Major Adult Malignant Glioma Disease Type
The major diseases includes glioblastoma multiforme, anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic oligoastrocytoma and others diseases.
Out of the Adult Malignant Glioma types, the glioblastoma multiforme disease is expected to exhibit the fastest growth over the forecast period